Thus, our results suggest that MUC5AC positive Quisinostat solubility dmso pancreatic cancer cells might be activated the

invasive potential via VEGFR-1 signaling pathway in an autocrine manner. To clarify effect of MUC5AC on tumor, we tried to test it using mouse model in vivo, because our in vitro study has the limitation with regard to true tumor microenvironment. However, we found no subcutaneous tumorigenesis, intraperitoneal metastasis or hepatic metastasis after inoculation of MUC5AC suppressed cells. Several studies have reported that VEGF is believed to be essential for growth and metastasis of solid malignancies in vivo [27, 33, 34]. Fukusawa et al previously reported that pancreatic tumor growth and metastasis in vivo were significantly suppressed by a soluble VEGFR chimer which binds VEGF-A with high affinity [35]. Although we showed no direct evidence that MUC5AC was associated with tumorigenesis of pancreatic tumor, it was likely that inhibition of MUC5AC might reduce VEGF production by tumor in vivo. For future study, it should be necessary to investigate the mechanism for association of MUC5AC with tumorigenesis in vivo. Conclusions buy ACY-738 The present work is the first demonstration of an association of

MUC5AC with pancreatic cancer cell invasion. MUC5AC might contribute to the progression of pancreatic cancer by inducing adhesiveness and invasiveness in ECM via VEGF overexpression, indicating that MUC5AC may be a potentially target in the treatment of pancreatic cancer. References 1. Bardeesy N, DePinho RA: Pancreatic cancer biology and genetics. Nature buy MK-8931 reviews 2002,2(12):897–909.PubMedCrossRef 2. Grzesiak JJ, Ho JC, Moossa AR, Bouvet M: The integrin-extracellular matrix axis

in pancreatic cancer. Pancreas 2007,35(4):293–301.PubMedCrossRef 3. Ellenrieder V, Adler G, Gress TM: Invasion and metastasis in pancreatic cancer. Ann Oncol 1999,10(Suppl 4):46–50.PubMedCrossRef 4. Kim YS, Gum J Jr, Brockhausen I: Mucin glycoproteins in neoplasia. Glycoconjugate journal 1996,13(5):693–707.PubMedCrossRef 5. Hollingsworth Decitabine manufacturer MA, Swanson BJ: Mucins in cancer: protection and control of the cell surface. Nature reviews 2004,4(1):45–60.PubMedCrossRef 6. Kanno A, Satoh K, Kimura K, Hirota M, Umino J, Masamune A, Satoh A, Asakura T, Egawa S, Sunamura M, et al.: The expression of MUC4 and MUC5AC is related to the biologic malignancy of intraductal papillary mucinous neoplasms of the pancreas. Pancreas 2006,33(4):391–396.PubMedCrossRef 7. Kim GE, Bae HI, Park HU, Kuan SF, Crawley SC, Ho JJ, Kim YS: Aberrant expression of MUC5AC and MUC6 gastric mucins and sialyl Tn antigen in intraepithelial neoplasms of the pancreas. Gastroenterology 2002,123(4):1052–1060.PubMedCrossRef 8. Takikita M, Altekruse S, Lynch CF, Goodman MT, Hernandez BY, Green M, Cozen W, Cockburn M, Sibug Saber M, Topor M, et al.: Associations between selected biomarkers and prognosis in a population-based pancreatic cancer tissue microarray. Cancer Res 2009,69(7):2950–2955.PubMedCrossRef 9.